Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib With or Without Everolimus in Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
NCT02143726Phase 2Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Oct 2014
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in Hurthle cell carcinoma of the thyroid (HCC), sponsored by Cancer and Leukemia Group B. Started Oct 2014; status: active, not recruiting.
02
Drugs
everolimus
03
Conditions
Hurthle cell carcinoma of the thyroid (HCC)
Beyond the preview
Go deeper on NCT02143726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02143726.